Year Founded
2022
Ownership
Private
Employees
~50
Therapeutic Areas
Hematology
Stage
Phase 1
Modalities
Antibody-based immunotherapy

Vega Therapeutics General Information

Currently conducting Phase 1a/1b study of VGA039 for von Willebrand disease

Contact Information

Website
Primary Industry
Biotech
Corporate Office
South San Francisco, California
United States

Drug Pipeline

VGA039
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Vega Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Vega Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Vega Therapeutics's complete valuation and funding history, request access »

Vega Therapeutics Investors

$40 million in financing to date (as of December 2022)
Investor Type: Venture Capital
Holding: Minority